This is a preview of subscription content, log in via an institution to check access.
Notes
This study also used a cost-consequence model to assess the costs and outcomes of eltrombopag, compared with romiplostim and W&R, in paediatric patients with cITP not responding to first-line therapies. The model had a 26-week time horizon and was populated with clinical data from two clinical trials using an indirect treatment comparison. The analysis was performed from a US payer's perspective.
References
Tremblay G, et al. Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia. ClinicoEconomics and Outcomes Research : 1 Nov 2018. Available from: URL: https://doi.org/10.2147/CEOR.S177324
Tremblay G, et al. Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia. ClinicoEconomics and Outcomes Research : 5 Nov 2018. Available from: URL: https://doi.org/10.2147/CEOR.S177338
Rights and permissions
About this article
Cite this article
Eltrombopag preferred in child and adult immune thrombocytopenia. PharmacoEcon Outcomes News 816, 14 (2018). https://doi.org/10.1007/s40274-018-5434-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5434-9